凯普生物(300639) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss for the fiscal year 2024, with estimated losses ranging from 480 million to 680 million CNY, compared to a profit of 140.47 million CNY in the same period last year[3] - The expected net loss attributable to shareholders after deducting non-recurring items is projected to be between 489.3 million and 689.3 million CNY, down from a profit of 113.19 million CNY in the previous year[3] Business Strategy - The company is focusing on the collaborative development strategy of three major business segments: molecular diagnostic products, medical testing services, and health management, which has led to overall losses in the medical testing segment due to increased costs[5] Non-Recurring Items - Non-recurring gains and losses are expected to impact the net profit by approximately 9.3 million CNY, primarily from government subsidies, investment income, and charitable donations[6] Asset Review - The company has conducted a comprehensive review of various assets, including accounts receivable and inventory, to assess potential impairments, particularly focusing on accounts receivable[6] Financial Reporting - The financial data in the earnings forecast has not been audited by a registered accounting firm, and the final figures will be disclosed in the company's 2024 annual report[4][7]